From Wikipedia, the free encyclopedia
Monoclonal antibody
Pateclizumab (MLTA3698A ) is an immunomodulator. It binds to
lymphotoxin alpha .
[1]
[2]
[3]
[4]
[5]
[6]
This drug was developed by
Genentech /
Roche .
References
^
World Health Organization (2011).
"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF) . WHO Drug Information . 25 (2). [
dead link ]
^
Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab ,
American Medical Association .
^ Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC (October 2014).
"Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)" . Arthritis Res. Ther . 16 (5): 467.
doi :
10.1186/s13075-014-0467-3 .
PMC
4243296 .
PMID
25359150 .
^ Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC (January 2012).
"Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial" . Arthritis Res. Ther . 14 (1): R6.
doi :
10.1186/ar3554 .
PMC
3392792 .
PMID
22225620 .
^ Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G (August 2016). "Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates". Reprod. Toxicol . 63 : 82–95.
doi :
10.1016/j.reprotox.2016.05.014 .
PMID
27211603 .
S2CID
41454952 .
^ Hirose T, Fukuma Y, Takeshita A, Nishida K (June 2018). "The role of lymphotoxin-α in rheumatoid arthritis". Inflamm. Res . 67 (6): 495–501.
doi :
10.1007/s00011-018-1139-6 .
PMID
29541795 .
S2CID
3910200 .